The most common patterns of resistance in EGFR-mutated NSCLC treated with osimertinib frontline are MET amplification, EGFR C797X-acquired mutation, and human epidermal growth factor 2 (HER2) amplification. The gene discussed is ERBB2; the disease is non-small cell lung carcinoma.